SCYNEXIS INC Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by SCYNEXIS, Inc. on February 4, 2022. The report discloses specific executive compensation arrangements approved by the Compensation Committee of the Board of Directors on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity grants and does not contain financial performance data.
Material Changes and Executive Compensation
On February 4, 2022, the company granted Restricted Stock Units (RSUs) and stock options to key executive officers under the 2014 Equity Incentive Plan:
- Marco Taglietti, M.D. (President and CEO):
- 87,200 RSUs vesting 50% annually over two years.
- 232,000 stock options with an exercise price of $4.60, vesting monthly over 48 months.
- David Angulo, M.D. (Chief Medical Officer):
- 51,100 RSUs vesting 50% annually over two years.
- 85,000 stock options with an exercise price of $4.60, vesting monthly over 48 months.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosure of the compensation grants.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2014 Equity Incentive Plan to assess remaining capacity for future grants.
- Confirm the current market price of SCYNEXIS common stock relative to the $4.60 exercise price of the new options.
- Review the vesting schedules to understand the retention timeline for the CEO and CMO.
- Check subsequent filings for any changes in executive leadership or compensation structure.